EZH2 and breast cancer: In breast cancer, where ANCR remains transcriptionally dormant, hyperactivity of EZH2 leads to an increase of the repressive H3K27me3 mark in promoter regions of EZH2 target genes (such as tumor-suppressors E-cadherin, HOXA10, etc.)which normally repress EMT progression [69].